Literature DB >> 7011348

Changes in blood pressure, plasma catecholamines and plasma renin activity during and after treatment with tiamenidine and clonidine.

B G Hansson, B Hökfelt.   

Abstract

1 Tiamenidine (Hoe 440) is an imidazoline with blood pressure lowering properties. Its pharmacology resembles that of clonidine. 2 The effect of both drugs on blood pressure, plasma noradrenaline (NA), plasma adrenaline (Ad), urinary catecholamines and plasma renin activity (PRA) was assessed in four previously untreated male hypertensive patients in a cross over study. 3 The maximum daily dose of tiamenidine was 3 mg. The maximum daily dose of clonidine was 450 micrograms. 4 During treatment, blood pressure, systolic and diastolic, supine and erect, fell on average between 12 and 15%. Levels of NA, Ad, PRA were reduced during treatment. 5 During withdrawal of either drug there was rebound of blood pressure and NA, Ad, PRA, overshooting baseline levels. 6 The withdrawal effects caused by clonidine were similar for tiamenidine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011348      PMCID: PMC1401688          DOI: 10.1111/j.1365-2125.1981.tb01105.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Improved technique for the fluorimetric estimation of catecholamines.

Authors:  U von EULER; F LISHAJKO
Journal:  Acta Physiol Scand       Date:  1961-04

2.  The over-shoot phenomenon on withdrawal of clonidine therapy.

Authors:  A D Goldberg; P R Wilkinson; E B Raftery
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

3.  Tiamenidine (Hoe 440), a new antihypertensive substance.

Authors:  E Lindner; J Kaiser
Journal:  Arch Int Pharmacodyn Ther       Date:  1974-10

4.  A sensitive double-isotope derivative assay for norepinephrine and epinephrine. Normal resting human plasma levels.

Authors:  K Engelman; B Portnoy
Journal:  Circ Res       Date:  1970-01       Impact factor: 17.367

5.  Studies on catecholamines, renin and aldosterone following Catapresan (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochloride) in hypertensive patients.

Authors:  B Hökfelt; H Hedeland; J F Dymling
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

6.  Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors:  J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

7.  [Central administration of tiamenidine and clonidine in normotensive and chronically renal hypertensive animals].

Authors:  E Lindner; B A Schölkens
Journal:  Verh Dtsch Ges Kreislaufforsch       Date:  1977

8.  Clonidine withdrawal. Mechanism and frequency of rebound hypertension.

Authors:  G G Geyskes; P Boer; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

9.  Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline.

Authors:  J L Reid; L M Wing; H J Dargie; C A Hamilton; D S Davies; C T Dollery
Journal:  Lancet       Date:  1977-06-04       Impact factor: 79.321

  9 in total
  3 in total

Review 1.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

Review 2.  Agmatine: biological role and therapeutic potentials in morphine analgesia and dependence.

Authors:  Soundar Regunathan
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

3.  Intrathecal Clonidine Pump Failure Causing Acute Withdrawal Syndrome With 'Stress-Induced' Cardiomyopathy.

Authors:  Hwee Min D Lee; Varuna Ruggoo; Andis Graudins
Journal:  J Med Toxicol       Date:  2016-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.